dc.contributor.author | Selenius, Jannica S. | |
dc.contributor.author | Silveira, Patricia P. | |
dc.contributor.author | Haapanen, Markus J. | |
dc.contributor.author | von Bonsdorff, Mikaela | |
dc.contributor.author | Lahti, Jari | |
dc.contributor.author | Eriksson, Johan G. | |
dc.contributor.author | Wasenius, Niko S. | |
dc.date.accessioned | 2024-05-29T10:53:47Z | |
dc.date.available | 2024-05-29T10:53:47Z | |
dc.date.issued | 2024 | |
dc.identifier.citation | Selenius, J. S., Silveira, P. P., Haapanen, M. J., von Bonsdorff, M., Lahti, J., Eriksson, J. G., & Wasenius, N. S. (2024). The brain insulin receptor gene network and associations with frailty index. <i>Age and Ageing</i>, <i>53</i>(5), Article afae091. <a href="https://doi.org/10.1093/ageing/afae091" target="_blank">https://doi.org/10.1093/ageing/afae091</a> | |
dc.identifier.other | CONVID_213740026 | |
dc.identifier.uri | https://jyx.jyu.fi/handle/123456789/95327 | |
dc.description.abstract | Objective: To investigate longitudinal associations between variations in the co-expression-based brain insulin receptor polygenic risk score and frailty, as well as change in frailty across follow-up.
Methods: This longitudinal study included 1605 participants from the Helsinki Birth Cohort Study. Biologically informed expression-based polygenic risk scores for the insulin receptor gene network, which measure genetic variation in the function of the insulin receptor, were calculated for the hippocampal (hePRS-IR) and the mesocorticolimbic (mePRS-IR) regions. Frailty was assessed in at baseline in 2001–2004, 2011–2013 and 2017–2018 by applying a deficit accumulation-based frailty index. Analyses were carried out by applying linear mixed models and logistical regression models adjusted for adult socioeconomic status, birthweight, smoking and their interactions with age.
Results: The FI levels of women were 1.19%-points (95% CI 0.12–2.26, P = 0.029) higher than in men. Both categorical and continuous hePRS-IR in women were associated with higher FI levels than in men at baseline (P < 0.05). In women with high hePRS-IR, the rate of change was steeper with increasing age compared to those with low or moderate hePRS-IR (P < 0.05). No associations were detected between mePRS-IR and frailty at baseline, nor between mePRS-IR and the increasein mean FI levels per year in either sex (P > 0.43).
Conclusions: Higher variation in the function of the insulin receptor gene network in the hippocampus is associated with increasing frailty in women. This could potentially offer novel targets for future drug development aimed at frailty and ageing. | en |
dc.format.mimetype | application/pdf | |
dc.language.iso | eng | |
dc.publisher | Oxford University Press | |
dc.relation.ispartofseries | Age and Ageing | |
dc.rights | CC BY-NC-ND 4.0 | |
dc.subject.other | insulin receptor (IR) | |
dc.subject.other | frailty | |
dc.subject.other | hippocampal (hePRS) | |
dc.subject.other | frailty index (FI) | |
dc.subject.other | insulin receptor | |
dc.subject.other | older people | |
dc.title | The brain insulin receptor gene network and associations with frailty index | |
dc.type | research article | |
dc.identifier.urn | URN:NBN:fi:jyu-202405294091 | |
dc.contributor.laitos | Liikuntatieteellinen tiedekunta | fi |
dc.contributor.laitos | Faculty of Sport and Health Sciences | en |
dc.type.uri | http://purl.org/eprint/type/JournalArticle | |
dc.type.coar | http://purl.org/coar/resource_type/c_2df8fbb1 | |
dc.description.reviewstatus | peerReviewed | |
dc.relation.issn | 0002-0729 | |
dc.relation.numberinseries | 5 | |
dc.relation.volume | 53 | |
dc.type.version | publishedVersion | |
dc.rights.copyright | © 2024 the Authors | |
dc.rights.accesslevel | openAccess | fi |
dc.type.publication | article | |
dc.subject.yso | ikääntyneet | |
dc.subject.yso | insuliini | |
dc.subject.yso | reseptorit (biokemia) | |
dc.subject.yso | gerastenia | |
dc.subject.yso | pitkittäistutkimus | |
dc.subject.yso | geenit | |
dc.subject.yso | hippokampus | |
dc.subject.yso | ikääntyminen | |
dc.format.content | fulltext | |
jyx.subject.uri | http://www.yso.fi/onto/yso/p2433 | |
jyx.subject.uri | http://www.yso.fi/onto/yso/p8422 | |
jyx.subject.uri | http://www.yso.fi/onto/yso/p38884 | |
jyx.subject.uri | http://www.yso.fi/onto/yso/p28376 | |
jyx.subject.uri | http://www.yso.fi/onto/yso/p14610 | |
jyx.subject.uri | http://www.yso.fi/onto/yso/p147 | |
jyx.subject.uri | http://www.yso.fi/onto/yso/p21117 | |
jyx.subject.uri | http://www.yso.fi/onto/yso/p5056 | |
dc.rights.url | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.relation.doi | 10.1093/ageing/afae091 | |
jyx.fundinginformation | Special thanks for the funding of the HBCS to the Finnish Foundation for Cardiovascular Research, Finnish Foundation for Diabetes Research, Juho Vainio Foundation, Academy of Finland, Novo Nordisk Foundation, Signe and Ane Gyllenberg Foundation, Samfundet Folkhälsan, Finska Läkaresällskapet, Liv och Hälsa, European Commission FP7 (DORIAN) Grant Agreement No. 278603 and EU H2020-PHC-2014-DynaHealth Grant No. 633595 and EU Horizon 2020 Award 733206 LIFECYCLE. P.P.S. is supported by Canadian Institutes of Health Research (CIHR, PJT-166066, PI P.P.S.). | |
dc.type.okm | A1 | |